Investigational drug · Phase 3
Fuzuloparib
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Phase 3Last checked: Nov 19, 2026Latest source record: Dec 31, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
13
Any phase or sponsor naming "Fuzuloparib"
First trial start
2021
Mar 18, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Fuzuloparib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Fuzuloparib" as an intervention, largest first.
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate CancerPivotal-lookingActive, not recruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT04691804 · 496 participants · Start Mar 18, 2021 · Primary completion Dec 31, 2026
Drug: Fuzuloparib , Abiraterone acetate and Prednisone; Fuzuloparib Placebo, Abiraterone acetate and Prednisone · For: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Sites: Anchorage, Alaska; Tucson, Arizona; Rancho Mirage, California · 147 sites in all
- PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBCPivotal-lookingRecruiting
Guangdong Provincial People's HospitalAcademic, hospital or other
NCT06533384 · 310 participants (planned) · Start Aug 1, 2024 · Primary completion Dec 31, 2026
Drug: As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Camrelizumab is made for adjuvant therapy.; 9 cycles of Camrelizumab as adjuvant therapy. · For: Triple-negative Breast Cancer
Sites: Guangzhou, China
- Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast CancerNot yet recruiting
Harbin Medical UniversityAcademic, hospital or other
NCT07752550 · 120 participants (planned) · Start Jul 30, 2026 · Primary completion Jul 30, 2028
Drug: Retlirafusp alfa+Nab-paclitaxel:; Retlirafusp alfa+Fluzoparib and 2 more · For: Triple-Negative Breast Cancer (TNBC)
Sites: Harbin, China
- A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian CancerPivotal-lookingNot yet recruiting
Qinglei GaoAcademic, hospital or other
NCT07355010 · 104 participants (planned) · Start Dec 30, 2025 · Primary completion Dec 30, 2028
Drug: fuzuloparib; Famitinib and 1 more · For: Ovarian Cancer
Xing XieAcademic, hospital or other
NCT04518501 · 50 participants (planned) · Start Jul 1, 2020 · Primary completion Dec 3, 2024
Drug: Arsenic trioxide Tablet +Fuzuloparib Capsules · For: Efficacy and Safety
Sites: Zhejiang, China
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT07033819 · 48 participants (planned) · Start Jun 25, 2025 · Primary completion Jun 20, 2027
Drug: Neoadjuvant therapy with fuzuloparib in combination with apatinib; Chemotherapy and 1 more · For: Ovarian Cancer
Sites: Beijing, China
Fudan UniversityAcademic, hospital or other
NCT05819060 · 44 participants (planned) · Start Apr 30, 2023 · Primary completion Sep 30, 2024
Drug: Fuzuloparib Combination with Bevacizumab · For: Recurrent Ovarian Cancer
Sites: Shanghai, China
- Radiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPCRecruiting
Jianbin BiAcademic, hospital or other
NCT06971211 · 40 participants (planned) · Start Nov 27, 2024 · Primary completion Oct 30, 2027
Drug: Intensity-modulated radiation therapy (IMRT) in combination with fluzoparib, abiraterone acetate tablets (II), and prednisone. · For: Metastatic Castration-resistant Prostate Cancer
Sites: Shenyang, China
- Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian CancerPivotal-lookingNot yet recruiting
The First Affiliated Hospital of Xiamen UniversityAcademic, hospital or other
NCT06188455 · 37 participants (planned) · Start Dec 1, 2024 · Primary completion Dec 1, 2025
Drug: Fluzoparib Capsules; Apatinib Mesylate Tablets · For: Ovarian Cancer
- Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian CancerNot yet recruiting
Fujian Cancer HospitalGovernment (non-federal)
NCT06600841 · 37 participants (planned) · Start Oct 1, 2024 · Primary completion Mar 1, 2026
Drug: Immunotherapy(Adebrelimab); immunotherapy(Adebrelimab) · For: Platinum-resistant Ovarian Cancer (PROC); Immunotherapy
Sites: Fuzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- An artificial intelligence-assisted PARP-1-targeted PET imaging agent [68Ga]Ga-DOTA-FZPF: From bench to clinic.
Ji M, Jiang C, Xi Y, et al. · Mater Today Bio 2026
- Hybrid surgical thromboembolectomy and crossover endovascular revascularization for acute lower-limb ischemia in a patient with active ovarian cancer receiving a PARP inhibitor (fuzuloparib): a case report and literature review.
Jiang Y, Wang G, Liu Z, et al. · Front Cardiovasc Med 2026
- Fuzuloparib plus apatinib maintenance in patients with platinum-sensitive recurrent ovarian cancer previously treated with first-line poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance (FLASH): an exploratory phase II trial.
Lv M, Lu J, Ma X, et al. · Int J Gynecol Cancer 2026
- Fuzuloparib in combination with apatinib versus fuzuloparib alone for recurrent ovarian cancer: a randomized, open-label, phase 2 trial.
Jiang G, Wang D, Wang W, et al. · J Ovarian Res 2026
- Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations: a cost-utility analysis.
Lang Y, Deng M, Yang J · Front Pharmacol 2026
- Cost-effectiveness of fuzuloparib, with or without apatinib, for BRCA mutation HER2-negative metastatic breast cancer in China.
Fu Y, Li Z, Xia Q, et al. · Front Pharmacol 2026
Also in development for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- OpevesostatMK-5684, ODM-208Phase 37 trials
Merck & Co. · Prostate Cancer Metastatic, Malignant Neoplasm, Metastatic Castration-resistant Prostate Cancer (mCRPC)
- PasritamigJNJ-78278343Phase 34 trials
Johnson & Johnson (Janssen) · Solid Tumor, Metastatic Castration-resistant Prostatic Neoplasms, Metastatic Castration-resistant Prostate Cancer (mCRPC)
- ARDTPhase 32 trials
Novartis · Metastatic Castration-Resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
- REGN5678NezastomigPhase 23 trials
Regeneron · Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
- GI-102Phase 22 trials
GI Innovation, Inc. · Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS)
- REGN4336Phase 22 trials
Regeneron · Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
- vudalimabPhase 22 trials
Xencor, Inc. · Ovarian Cancer, Clear Cell Carcinoma, Endometrial Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.